NCT05364619

Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection

Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection Treatment in the Elderly Patient, a Multi-center, Randomized, Controlled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, randomized controlled trial. The aim of the study is to evaluate the efficacy and safety of the Qingre Huashi Granules combined the modified dual therapy (or called high dose dual therapy) for Helicobacter pylori infection specifically in geriatric patients, compared with the bismuth containing quadruple therapy. A total of 160 eligible patients will be enrolled in 4 hospitals. The eradication rate, symptoms, and the adverse events will be recorded and analyzed.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Qingre Huashi Granules combined the modified dual therapy	Qingre Huashi Granules combined the modified dual therapy for 14 days
DRUG	Bismuth containing quadruple therapy	Bismuth containing quadruple therapy for 14 days

Timeline

• Start date: 2022-08-05
• Primary completion: 2024-12-01
• Completion: 2024-12-31
• First posted: 2022-05-06
• Last updated: 2022-10-18

Locations

3 sites across 1 country: China